Immuno-Biological Laboratories (4570) · InitiativeFirst statedLatest Other Disclosures (2026-06-24): "Advanced"
Business partnership with artience in life sciences
First written in FY2026-H1. 1 of 2 entries say "Advanced", first in 2026-06-24. Latest entry: 2026-06-24.
2entries
2years
1from disclosures
How it moved
Same theme, other companies
Business partnership with artience in life sciencesA theme 1 companies write about · 0 as a headwind · 1 as a tailwind
No other company in this theme has enough history to compare yet.
Full recordFilings, disclosures and news, newest first
- 2026-06-24AdvancedOther Disclosures
「Since beginning the business alliance on 1 July 2025, artience and the Company have been working to develop more accurate and stable in vitro diagnostic products and testing reagents that do not require proteins of biological origin by combining the Company’s technologies relating to antibodies, reagent kits, and in vitro diagnostic products with artience’s polymer materials and chemical synthesis technologies.」
The business alliance, which had previously remained at the stage of signing a basic agreement, progressed to specific results: development of an sCLEC-2 measurement ELISA kit, a reduction of BSA use by more than 90% through artience’s chemically synthesized additives, and planned sales launch in mid-July 2026. - FY2026-H1First statedAnnual report
「Basic agreement concerning a business alliance in the life sciences business」
artience Co., Ltd. entered into a basic agreement concerning a business alliance in the life sciences business on 1 July 2025. The agreement period is stated as running from 1 July 2025 to 30 June 2026.